Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Shire Pharmaceutical Development |
---|---|
Information provided by: | Shire Pharmaceutical Development |
ClinicalTrials.gov Identifier: | NCT00413634 |
Age related differences in response to a drug could arise from variation in PK and/or pharmacodynamic (PD) profiles between age groups. Whilst the efficacy and safety profile of anagrelide is well established through a well-documented clinical trial programme in patients of all ages, no formal studies have been carried out to investigate whether the PK profile of anagrelide and its metabolites is altered with age.
This study is designed to allow comparisons to be made in terms of pharmacokinetics of anagrelide and its metabolites between elderly (>65 years) and young (18-50 years) ET patients
Condition | Intervention | Phase |
---|---|---|
Essential Thrombocythaemia |
Drug: anagrelide hydrochloride |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Phase II, Open-Label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia.A Phase II, Open-Label, Multicentre, Pharmacokinetic, Pharmacodynamic and Safety Study of Anagrelide Hydrochloride in Young (18-50 Years) and Elderly (≥ 65 Years) Patients With Essential Thrombocythaemia |
Estimated Enrollment: | 24 |
Study Start Date: | August 2006 |
Study Completion Date: | March 2008 |
Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: anagrelide hydrochloride
Anagrelide hydrochloride 0.5mg per capsule; patients will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the patient specific anagrelide dose will be administered from a controlled study specific supply.
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Spain | |
Hospitl Del Mar | |
Barcelona, Spain | |
Sweden | |
Uppsala Akademiska Sjukhus | |
Uppsala, Sweden, 75185 | |
Sweden, Lulea | |
Quintiles Hermelinen | |
Sandviksgatan, Lulea, Sweden | |
Sweden, Uppsala | |
Quintiles AB Phase I Unit | |
Strandbodgatan, Uppsala, Sweden | |
United Kingdom | |
Belfast City Hospital | |
Belfast, United Kingdom |
Principal Investigator: | Carlos Besses Raebel | Spain |
Responsible Party: | Shire ( Timothy Whitaker, M.D. ) |
Study ID Numbers: | SPD422-203 |
Study First Received: | December 19, 2006 |
Last Updated: | July 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00413634 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency; Germany: Federal Institute for Drugs and Medical Devices; Sweden: Medical Products Agency; Spain: Ministry of Health |
Essential thrombocytosis Hematologic Diseases Blood Coagulation Disorders Blood Platelet Disorders Myeloproliferative Disorders Hemostatic Disorders Thrombocytopathy |
Hemorrhagic Disorders Hemorrhagic thrombocythemia Thrombocytosis Thrombocythemia, Hemorrhagic Bone Marrow Diseases Anagrelide |
Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Hematologic Agents |
Platelet Aggregation Inhibitors Fibrinolytic Agents Cardiovascular Agents Pharmacologic Actions |